NBDHEX
Based on 2 publication(s) in Google Scholar
NBDHEX is a potent glutathione S-transferase P1-1 (GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.56%
- CAS No.: 787634-60-0
- Formula: C12H15N3O4S
- Molecular Weight:297.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Lung Cancer Compound Library
HY-L075
-
Cuproptosis Compound Library
HY-L133
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Amino Acid Metabolism Compound Library
HY-L189
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NBDHEX
More
Biological Activity
Glutathione S-transferase P1-1 (GSTP1-1)[1];
Apoptosis[1];
Autophagy[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 143B | IC50 |
4.08 μM
Compound: NBDHEX
|
Antiproliferative activity against human 143B cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human 143B cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 33529017] |
| A549 | IC50 |
2.88 μM
Compound: NBDHEX
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 33529017] |
| HOS | IC50 |
1.24 μM
Compound: NBDHEX
|
Antiproliferative activity against human HOS cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human HOS cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 33529017] |
| HUVEC | IC50 |
0.5 μM
Compound: NBDHEX
|
Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33529017] |
| L02 | IC50 |
1.56 μM
Compound: NBDHEX
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33529017] |
| U2OS | IC50 |
0.6 μM
Compound: 1, MC2754, NBDHEX
|
Cytotoxicity against human U2OS cells assessed as cell survival after 48 hrs SRB assay
Cytotoxicity against human U2OS cells assessed as cell survival after 48 hrs SRB assay
|
[PMID: 25462236] |
NBDHEX (0.05-20 μM; 48 hours; H69 and H69AR cells) is cytotoxic toward cell lung cancer H69 and H69AR cells[2].
NBDHEX (0-5 μM; 24 hours; H69AR cells) treatment results in a dose-dependent apoptosis in the H69AR cell line[2].
NBDHEX (3 μM; 1-12 hours; H69AR cells) treatment increases the phosphorylation of JNK/c-Jun in H69AR cells in a time-dependent fashion[2].
NBDHEX treatment shows a marked increase in phosphorylation of p38MAPK, and also increases GSSG content in a time-dependent manner in H69 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H69 and H69AR cells
-
Concentration:0.05-20 μM
-
Incubation Time:48 hours
-
Result:The dose-response profiles revealed a good cytotoxic activity both in sensitive H69 cell line (LC50 of 2.3 μM) and in its Adriamycin-resistant counterpart H69AR (LC50 of 4.5 μM).
-
Cell Line:H69AR cells
-
Concentration:0 μM, 0.5 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM
-
Incubation Time:24 hours
-
Result:Resulted in a dose-dependent apoptosis in the H69AR cell line.
-
Cell Line:H69AR cells
-
Concentration:3 μM
-
Incubation Time:1 hour,3 hours, 6 hours, 12 hours
-
Result:Increased the phosphorylation of JNK/c-Jun in H69AR cells in a time-dependent fashion.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID female mice (4-5 weeks) injected with Me501cells[3]
-
Dosage:0.8 mg/kg/day, 8.0 mg/kg/day or 80 mg/kg/day
-
Administration:Oral administration; daily; for 15 days
-
Result:A statistically significant tumour inhibition (approximately 70%) was observed.
Chemical Information
-
CAS No. 787634-60-0
-
Appearance Solid
-
Molecular Weight 297.33
-
Formula C12H15N3O4S
-
Color Light yellow to yellow
-
SMILES
OCCCCCCSC1=CC=C([N+]([O-])=O)C2=NON=C21
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Augmentation of the Benzyl Isothiocyanate-Induced Antiproliferation by NBDHEX in the HCT-116 Human Colorectal Cancer Cell Line. [Abstract]2025 Aug 22;26(17):8145. PMID: 40943071 -
Reprod Sci
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) Hexanol Inhibits Proliferation and Induces Apoptosis of Endometriosis by Regulating Glutathione S-Transferase Mu Class 4. [Abstract]2023 Oct;30(10):2945-2961. PMID: 36928896
Solvent & Solubility
DMSO : 125 mg/mL (420.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sha HH, et al. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound. Biosci Rep. 2018 Feb 13;38(1). pii: BSR20171440. [Content Brief]
[2]. Filomeni G, et al. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther. 2008 Feb;7(2):371-9. [Content Brief]
[3]. Pellizzari Tregno F, et al. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer. 2009 Sep;45(14):2606-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3633 mL | 16.8163 mL | 33.6327 mL | 84.0817 mL |
| 5 mM | 0.6727 mL | 3.3633 mL | 6.7265 mL | 16.8163 mL | |
| 10 mM | 0.3363 mL | 1.6816 mL | 3.3633 mL | 8.4082 mL | |
| 15 mM | 0.2242 mL | 1.1211 mL | 2.2422 mL | 5.6054 mL | |
| 20 mM | 0.1682 mL | 0.8408 mL | 1.6816 mL | 4.2041 mL | |
| 25 mM | 0.1345 mL | 0.6727 mL | 1.3453 mL | 3.3633 mL | |
| 30 mM | 0.1121 mL | 0.5605 mL | 1.1211 mL | 2.8027 mL | |
| 40 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL | 2.1020 mL | |
| 50 mM | 0.0673 mL | 0.3363 mL | 0.6727 mL | 1.6816 mL | |
| 60 mM | 0.0561 mL | 0.2803 mL | 0.5605 mL | 1.4014 mL | |
| 80 mM | 0.0420 mL | 0.2102 mL | 0.4204 mL | 1.0510 mL | |
| 100 mM | 0.0336 mL | 0.1682 mL | 0.3363 mL | 0.8408 mL |
Powered by Bioz